RECENT ADVANCES IN THE TREATMENT OF HIV INFECTION-A REVIEW
DOI:
https://doi.org/10.61841/jyn1ve41Keywords:
HIV infection, CCR5 protein, Nucleotide reverse transcriptase inhibitors, Non-nucleotide reverse transcriptase inhibitors, ReplicationAbstract
HIV is the leading cause of mortality and morbidity worldwide. HIV infection is considered a medical apocalypse in certain age periods because it caused massive infection spread . However many interpretations and inventions in the treatment of HIV infection, it is still considered a major disease burden because it directly affects the immune cells of individuals and makes them more vulnerable to common infections. Advances in HIV/AIDS therapy were quick and well-exposed. An improved understanding of HIV pathogenesis has shown the need for aggressive antiretroviral therapy in most HIV-infected people. At least three combinations of drugs are needed to suppress viral replications. In addition, the capacity of pharmaceutical firms to formulate such effective medications into fixed-dose formulations offers innovative new pill stress reduction techniques, thus ensuring adherence and reducing the development of drug resistance. However, the excitement with which these new drugs were greeted has been tempered by the fact of restricted access in the developing world, further illustrating the gap in the battle against HIV/AIDS between the rich and poor countries. Such therapies would require proper political will and medication access to low- and middle-income countries. Developing countries' goal continues to increase the scope of ART, but in order to tackle toxicity and drug resistance, both of which threaten the viability of these initiatives, new drugs are also required. Nowadays, recent studies focus on obtaining viral sequences found in newly infected individuals to identify and examine the features of all transmitted pathogens, which could provide potential targets to develop an HIV vaccine. This study focuses mainly on the recent advanced methodologies used in HIV treatment.
Downloads
References
1. Zulfiqar HF, Javed A, Sumbal, Afroze B, Ali Q, Akbar K, et al. HIV Diagnosis and Treatment through
Advanced Technologies. Front Public Health. 2017 Mar 7;5:32.
2. Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of
Infection: a brief overview. Ann is Super Sanita. 2010; 46(1):5–14.
3. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol. 2004 May;30(1):1–10.
4. Costin JM. Cytopathic mechanisms of HIV-1. Virol J. 2007 Oct 18;4:100.
5. Samuel AR, Devi MG. Geographical distribution and occurrence of endemic goiter. Research Journal of
Pharmacy and Technology. 2015;8(8):973–8.
6. Organization WH, Others. UNAIDS: Global Report: UNAIDS report on the global AIDS epidemic.
Geneva: WHO. 2010;10.
7. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al.
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force
Recommendation Statement. JAMA. 2019 Jun 11;321(22):2203–13.
8. Baheerati MM, Devi RG. Obesity in relation to infertility. Research Journal of Pharmacy and Technology.
2018;11(7):3183–5.
9. Meulendyke KA, Croteau JD, Zink MC. HIV life cycle, innate immunity and autophagy in the central
nervous system. Curr Opin HIV AIDS. 2014 Nov;9(6):565–71.
10. Fathima F. Preetha. Evaluation of Thyroid Function Test in Obese Patients. Asian J Pharm Clin Res.
2016;9(3):353–5.
11. Yousaf MZ, Zia S, Babar ME, Ashfaq UA. The epidemic of HIV/AIDS in developing countries; the
current scenario in Pakistan. Virol J. 2011 Aug 12;8:401.
12. Azevedo-Pereira JM, Santos-Costa Q. HIV Interaction With Human Host: HIV-2 As a Model of a Less
Virulent Infection. AIDS Rev. 2016 Jan;18(1):44–53.
13. Harsha L, Priya J, Shah KK, Reshmi B. Systemic approach to management of neonatal jaundice and
prevention of kernicterus. Research Journal of Pharmacy and Technology. 2015;8(8):1087–92.
14. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health
implications. Science. 2000 Jan 28;287(5453):607–14.
15. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme A-M. Tracing the origin and history
of the HIV-2 epidemic. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6588–92.
16. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol.
2004 Jan;2(1):33–42.
17. Levy JA. The transmission of AIDS: the case of the infected cell. JAMA. 1988 May 27;259(20):3037–8.
18. Ronen K, Sharma A, Overbaugh J. HIV transmission biology: translation for HIV prevention. AIDS. 2015
Nov;29(17):2219–27.
19. Dave PH, Others. Pathogenesis and Novel Drug for Treatment of Asthma-A Review. Research Journal of
Pharmacy and technology. 2016;9(9):1519–23.
20. Arora DR, Gautam V, Gill PS, Mishra N. Recent advances in antiretroviral therapy in HIV infection. J
Indian Med Assoc. 2010 Jan;108(1):29–34.
21. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug
Resistance mutations in HIV-1. Top Antivir Med. 2011 Nov;19(4):156–64.
22. Grady C. The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a Preventive
HIV Vaccine. Indiana University Press; 1995. 208 p.
23. Rubens M, Ramamoorthy V, Saxena A, Shehadeh N, Appunni S. HIV Vaccine: Recent Advances, Current
Roadblocks and Future Directions. J Immunol Res. 2015 Oct 22;2015:560347.
24. Dowdle W. The search for an AIDS vaccine. Public Health Rep. 1986 May;101(3):232–3.
25. Moss AR, Bacchetti P. Natural history of HIV infection. AIDS. 1989 Feb;3(2):55–61.
26. Priya J, Devi G, Others. Evaluation of Muscular Endurance among Dentists. Indian Journal of Public
Health Research & Development [Internet]. 2019;10(10).
27. Priya AJ, Devi G, Others. Physical Fitness among the Dental Physician, Dental Undergraduates and
Postgraduate Students. Indian Journal of Public Health Research & Development. 2019;10(10):223–6.
28. Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res. 2010
Jan; 85(1):25–33.
29. Pilcher CD, Joaki G, Hoffman IF, Martinson FEA, Mapanje C, Stewart PW, et al. Amplified transmission
of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection.
AIDS. 2007 Aug 20;21(13):1723–30.
30. Shruthi M, Preetha S. Effect of Simple Tongue Exercises in Habitual Snorers. Research Journal of
Pharmacy and Technology. 2018;11(8):3614–6.
31. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral
lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS.
1998 May 7;12(7):F51–8.
32. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov
2;382(9903):1525–33.
33. Palepu A, Tyndall MW, Chan K, Wood E, Montaner JSG, Hogg RS. Initiating highly active antiretroviral
therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV
treatment outcomes. Antivir Ther. 2004 Oct;9(5):713–9.
34. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral Treatment
of Adult HIV Infection: 2008 Recommendations of the International AIDS Society–USA Panel. JAMA.
2008 Aug 6;300(5):555–70.
35. Swathy S, Sethu VG. Acupuncture and lower back pain. Research Journal of Pharmacy and Technology.
2015;8(8):991–3.
36. Iyer PK, Devi RG, Priya AJ. A Survey Study on Causes, Treatment, and Prevention of Onychocryptosis.
Indian Journal of Public Health Research & Development. 2019;10(8):807–11.
37. Temesgen Z, Siraj DS. Raltegravir: first-in-class HIV integrase inhibitor. Ther Clin Risk Manag. 2008
Apr; 4(2):493–500.
38. Gayatri DR, Sethu G. EVALUATION OF ADENOIDS BY ORONASAL AND NASAL SPIROMETRY.
Evaluation [Internet]. 2018;11(10).
39. Timothy CN, Devi RG, Priya AJ. Evaluation of Peak Expiratory Flow Rate (PEFR) in Pet Owners. Indian
Journal of Public Health Research & Development. 2019;10(8):803–6.
40. Rj I, Devi G. Role of environmental factors on sleep patterns of different age groups: A survey-based study. Asian J Pharm Clin Res. 2016;9(6):124–6.
41. Renuka S, Sethu G. Regeneration after Myocardial Infarction. Research Journal of Pharmacy and Technology. 2015;8(6):738–41.
42. Choudhari S, Jothipriya MA. Non-alcoholic fatty liver disease. Research Journal of Pharmacy and Technology. 2016;9(10):1782–5.
43. Farhat Yaasmeen Sadique Basha, Rajeshkumar S, Lakshmi T, Anti-inflammatory activity of Myristica fragrance extract. Int. J. Res. Pharm. Sci., 2019; 10(4), 3118-3120 DOI: https://doi.org/10.26452/ijrps.v10i4.1607
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
